Amgen At Supreme Court: What’s The Threshold For Securities Fraud?
This article was originally published in The Pink Sheet Daily
Executive Summary
Justices address whether plaintiffs need to prove company misrepresentations are material at the class certification stage; pension funds claim Amgen misrepresented the safety of Aranesp and Epogen prior to an FDA advisory committee meeting.